This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-15. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Hasegawa, Shuichi; Levin, Christoph; Radner, Karen, eds. (2018). The Last Days of the Kingdom of Israel. Walter de Gruyter GmbH & Co KG. ISBN 978-3-11-056660-4. Joffe, Alexander H. (2002). "The Rise of Secondary States in the Iron Age Levant". Journal of the Economic and Social History of the Orient. 45 (4): 425–467. doi:10.1163/156852002320939311. JSTOR 3632872. McNutt, Paula (1999). Reconstructing the Society of Ancient Israel. Westminster John Knox Press. ISBN 978-0-664-22265-9. Archived from the original on 1 July 2023. Retrieved 14 August 2015. Manzur, Ibn (1979). "SMR". Lisan al Arab. Vol. 21. Al-dar al-Misriya li-l-talif wa-l-taryamar. ISBN 978-0-866-85541-9. Mendels, D. (1987). The Land of Israel as a Political Concept in Hasmonean Literature: Recourse to History in Second Century B.C. Claims to the Holy Land. Texte und Studien zum antiken Judentum. J.C.B. Mohr. ISBN 978-3-16-145147-8. Retrieved 7 December 2020. Na'aman, Nadav (2011). "The Exodus Story: Between Historical Memory and Historiographical Composition". Journal of Ancient Near Eastern Religions. 11: 39–69. doi:10.1163/156921211X579579. Redmount, Carol A. (2001) [1998]. "Bitter Lives: Israel in and out of Egypt". In Coogan, Michael D. (ed.). The Oxford History of the Biblical World. Oxford and New York: Oxford University Press. pp. 58–89. ISBN 978-0-19-513937-2. Archived from the original on 3 April 2023. Retrieved 26 June 2023. Tetley, M. Christine (2005). The Reconstructed Chronology of the Divided Kingdom. Eisenbrauns. pp. 105–. ISBN 978-1-57506-072-9. Tubb, Jonathan N. (1998). Canaanites.
Gioia Tauro harbor, completed in 1985 was conceived as a trading port for the steel plant, was later used as a transit port: from the outset, it was under the control of the Piromalli and Molè clans, who used it to import drugs and counterfeit goods. In the 1990s, in order to quell the murder spree (such as the 1991 murder of Judge Antonino Scopelliti, who was working on the Palermo Maxi Trial), Operation Riace was implemented, bringing the army (1350 personnel) to bear. Other initiatives included “Wall Street,” ‘Count Down,’ ‘Hoca Tuca,’ ‘North-South,’ ‘Belgium,’ and ‘Fine,’ which involved many 'ndrine and ended the Siderno Group, a drug trafficking consortium between Canada and Calabria.
Swedish foreign affairs commentator and terrorism expert Wolfgang Hansson compared Trump's actions to Russian hybrid warfare, stating that "Trump realised that taking over Greenland militarily would be expensive, risky, and look very bad, but hybrid warfare is cheap and easy to deny".
The Weimaraner is of medium to large size: dogs stand some 59 to 70 cm at the withers, bitches about 57 to 65 cm; weights are in the range 30–40 kg for dogs, 25–35 kg for bitches. The coat may be either short or long; a double coat of intermediate length is sometimes seen. The coat may be mouse-grey, roe-grey or silver-grey in various shades, or of a colour intermediate between these; minor white markings to the feet and chest are tolerated. The eyes are amber, ranging from pale to dark; the ears are pendent, with rounded tips. Among the neurological diseases associated with the Weimaraner are cerebellar hypoplasia, hypomyelinogenesis and spinal dysraphism. Other diseases or defects to which it has some genetic or statistical predisposition include corneal dystrophy, distichiasis, entropion, eversion of the cartilage of the nictitating membrane, generalised demodicosis, medial canthal pocket syndrome, refractory corneal ulceration and XX sex reversal, and also – in dogs only – Weimaraner neutrophil dysfunction, pododermatitis and tricuspid dysplasia. A 2024 UK study found a median lifespan of 12.8 years for the breed compared to an average of 12.7 for purebreeds and 12 for crossbreeds.
When endothelial damage exposes the underlying extracellular matrix, adhesion begins in which von Willebrand factor binds to collagen, causing the recruitment of platelets through interactions with glycoprotein Ib receptors. This initial attachment allows platelets to stick to the damaged vessel wall. Upon adhesion, platelets undergo morphological changes and release bioactive molecules from their granules—signifying activation. Molecules like ADP and thromboxane A₂ increase the activation signal, which calls more circulating platelets to the injury site. Activation also leads to the expression of phosphatidylserine on the membrane surface. This acts as a catalytic platform for the coagulation cascade. Lastly, aggregation is performed as activated platelets express glycoprotein IIb/IIIa receptors, which bind fibrinogen and facilitate platelet-platelet interactions. This, in turn, leads to clot formation and stabilization and reinforces the platelet plug by converting fibrinogen into an insoluble fibrin mesh. Platelets also have a key role in immune responses, inflammation, and tissue repair through their interactions with leukocytes and endothelial cells. To recruit immune cells to injury sites, activated platelets can release cytokines and chemokines such as platelet factor 4 (PF4) and transforming growth factor-beta (TGF-β). They also form platelet-leukocyte aggregates, which further enhance neutrophil and monocyte activation, in turn supporting pathogen clearance and inflammatory signaling.
Sources: en.wikipedia.org
=== Menstrual leave policy === In October 2025, the Karnataka cabinet approved a policy providing women employees with one paid menstrual-leave day per month, amounting to up to 12 days annually Lad described the measure as a progressive labour policy and said it was intended to support women's health and participation in the workforce. The policy was subsequently implemented through government orders. In December 2025, Karnataka extended the paid menstrual-leave benefit to women government employees, including contractual workers.
When her husband died in 1882 she told the Boston Globe that malicious animal magnetism had killed him. While Eddy argued that reality was entirely spiritual (and therefore entirely good), it remained true that human beings were affected by their belief in evil, which meant it had power, even if the power was an illusion. Evil was "like a bankrupt to whom credit is still granted", writes Wilson. To defend herself against it, Eddy organized "watches", during which students (known as mental or metaphysical workers) would give "adverse treatment" to her enemies. This was called "taking up the enemy in thought". According to former students, Eddy would tell them to say (often with Richard Kennedy in mind): "You are affected as you wish to affect me. Your evil thought reacts upon you," then to call Kennedy bilious, consumptive or poisoned by arsenic. Eddy set up what she called a secret society of her students (known as the P. M., or private meeting) to deal with malicious animal magnetism, but she said that the group only met twice. In her later years, Wilson writes, Eddy came to see animal magnetism as an impersonal force and concluded that individuals ought not to be "taken up in thought". From 1890 she felt that her students were focusing on it too much, and thereafter public discussion of malicious animal magnetism declined, although Gottschalk adds that it continued to play an important role in the teaching of Christian Science. Adam H.
==== Traumatic calcinosis cutis ==== Traumatic calcinosis cutis is a cutaneous condition characterized by calcification of the skin resulting from the deposition of calcium and phosphorus often resulting from occupational exposure, as in cases reported in oil-field workers and coal miners.
== Internal R&D Department == In recent years, GNC has faced challenges due to changing consumer preferences and increased competition in the health and wellness market. The company has responded by rebranding itself and focusing on digital sales and marketing. GNC collaborates with healthcare professionals, academic institutions and researchers worldwide to investigate various technologies, botanical extracts, and nutrients. They have a team of quality and research scientists Franchising Science Beyond Raw Internal R&D Department who conduct tests on nutritional ingredients sourced from different parts of the world. Additionally, GNC implements a "Truth in Labeling Policy", where their scientists, nutritionists and quality assurance professionals independently validate all the information stated on their product labels.
Statistical, likelihood-based approaches: Statistical, likelihood-based iterative expectation-maximization algorithms such as the Shepp–Vardi algorithm are now the preferred method of reconstruction. These algorithms compute an estimate of the likely distribution of annihilation events that led to the measured data, based on statistical principles. The advantage is a better noise profile and resistance to the streak artifacts common with FBP, but the disadvantage is greater computer resource requirements. A further advantage of statistical image reconstruction techniques is that the physical effects that would need to be pre-corrected for when using an analytical reconstruction algorithm, such as scattered photons, random coincidences, attenuation and detector dead-time, can be incorporated into the likelihood model being used in the reconstruction, allowing for additional noise reduction. Iterative reconstruction has also been shown to result in improvements in the resolution of the reconstructed images, since more sophisticated models of the scanner physics can be incorporated into the likelihood model than those used by analytical reconstruction methods, allowing for improved quantification of the radioactivity distribution. Research has shown that Bayesian methods that involve a Poisson likelihood function and an appropriate prior probability (e.g., a smoothing prior leading to total variation regularization or a Laplacian distribution leading to
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.